Cidara Therapeutics Inc (CDTX) — Cash Flow-to-Debt Ratio
Cidara Therapeutics Inc (CDTX) has a Cash Flow-to-Debt Ratio of -0.42x as of September 2025, meaning its operating cash flow of $-40.62 Million could theoretically repay 0% of its total liabilities ($96.26 Million) in one year. See Cidara Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cidara Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cidara Therapeutics Inc across 12 annual periods. Also explore Cidara Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cidara Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Cidara Therapeutics Inc. For market capitalisation and broader financial context, see how much is Cidara Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.43x | $-176.53 Million | $51.49 Million | ▼ -1050.0% |
| 2023 | -0.30x | $-22.43 Million | $75.24 Million | ▲ +35.2% |
| 2022 | -0.46x | $-28.47 Million | $61.92 Million | ▲ +2.0% |
| 2021 | -0.47x | $-25.23 Million | $53.75 Million | ▲ +57.1% |
| 2020 | -1.09x | $-54.41 Million | $49.71 Million | ▼ -19.5% |
| 2019 | -0.92x | $-28.53 Million | $31.14 Million | ▲ +67.7% |
| 2018 | -2.84x | $-56.70 Million | $19.97 Million | ▼ -9.7% |
| 2017 | -2.59x | $-49.91 Million | $19.29 Million | ▼ -22.2% |
| 2016 | -2.12x | $-39.77 Million | $18.78 Million | ▲ +50.6% |
| 2015 | -4.28x | $-25.96 Million | $6.06 Million | ▼ -80.3% |
| 2014 | -2.37x | $-7.71 Million | $3.25 Million | ▼ -262.3% |
| 2013 | -0.66x | $-1.05 Million | $1.60 Million | — |